Martin Nutraceuticals Inc. Opens Negotiations to Enter the $900 Million Nutraceutical and Supplement Australian Market.RENO, NV -- Martin Nutraceuticals Inc. (PINKSHEETS: MNCL MNCL Maintenance Non-Computing (Module) Load .PK) is pleased to announce that it entered into negotiations with JPS JPS Jewish Publication Society JPS John Peter Smith (Hospital; Texas) JPS Justice & Public Safety JPS Jean Piaget Society JPS Juvenile Polyposis Syndrome JPS Joint Planning Staff Trading Co., a company focused on distribution of supplements and natural products in Australia. JPS Trading Co. will represent all of Martin's flagship products, Arthrizyme, Oxygenol and Maximum Slim, and will also represent Dr. Martin's book, Medical Crisis - Secrets Your Doctor Won't Share With You. The marketing strategy by JPS will focus on mass distribution of Martin's flagship ingestible products into major retail and supplement centers. The strategy of marketing of the book will follow the North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. model and will be sold through a direct sales DRTV DRTV Direct Response Television (media) (infomercial) campaign. "This could be a fantastic opportunity for Martin Nutraceuticals," states Harvey Panesar, President of Martin Nutraceuticals Inc., "We are very excited about the possibilities of entering the Australian market, which is an absolute bonus since we have been focusing on getting our infomercial/DRTV campaign to air in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. . We were not actively searching for other markets outside of North America, but when this opportunity arose, we could not turn it down - it just made sense to at least explore where it could lead." The Australian market size for nutraceuticals has been consistently rising over the last few years. The current market size for nutraceuticals in Australia has exceeded over $900 million; largely due in part to 60% of the Australian population currently using a nutraceutical product, which equivocates to 7.5 million Australian consumers. Source: Aztec Information System For more information, please contact Investor Relations Investor relations The process by which the corporation communicates with its investors. at (973) 351-3868 or http://www.martinnutra.com/. About Martin Nutraceuticals Inc. Martin Nutraceuticals Inc. is a company focused on providing a better health and lifestyle through natural products. Martin Nutraceuticals flagship products include Arthrizyme(TM) for general joint pain and Oxygenol(TM) for anti-oxidation and Maximum Slim(TM) for weight control. Arthrizyme(TM) is a unique blend of systemic enzymes proven to rapidly reduce inflammation in joints and muscles. Arthrizyme(TM) is not limited to anti-inflammatory effects; it also assists the body in the healing process by breaking down fibrin fibrin: see blood clotting. in joints and muscles. Arthrizyme(TM) differs from all other natural arthritis remedies and was designed to work for all types of arthritis and in all joints of the body. Arthrizyme(TM) is fast acting, usually improving symptoms within the first few days. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The risks and uncertainties that may affect the operations, performance development and results of the Company's business include but are not limited to fluctuations in financial results, availability and customer acceptance of our products and services, the impact of competitive products, services and pricing, general market trends and conditions. |
|
||||||||||||||

Printer friendly
Cite/link
Email
Feedback
Reader Opinion